Novel Immunotoxin and IGF Therapy for Strabismus
Novel Immunotoxin and IGF Therapy for Strabismus
批准号:
9920850
负责人:
LINDA K. MCLOON
金额:
$3.44万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2004
资助国家:
美国
项目状态:
已结题
起止时间:
2004-01-01 至 2023-04-30
关键词:
AdultAftercareAmblyopiaAntibodiesBilateralBindingBiochemicalBlindnessBrainBrain StemCell NucleusChildChildhoodCiliary Neurotrophic FactorCommunicationDataDepth PerceptionDevelopmentDiagnosisDiseaseDoseEarly treatmentEffectivenessEtiologyEyeEye MovementsFailureFutureGenesGoalsGrowth FactorHumanIGF1 geneIGF2 geneImmunotoxinsInfantInsulinInsulin-Like Growth Factor IILateralLeadLeftLiteratureMasksMedialMethodsMonkeysMorphologyMotor NeuronsMuscleMuscle functionMutationNerveNeuronsOcular Motility DisordersOperative Surgical ProceduresOryctolagus cuniculusOutcomePatientsPeptidesPeripheralPhysiologicalPlant RootsPlayPublishingRecording of previous eventsRoleSignal PathwaySignal TransductionStrabismusStructureSupplementationSystemTestingTreatment EfficacyVisionVisual Acuitybasecombinatorialdeprivationeffective therapyefficacy testingexperimental studyglial cell-line derived neurotrophic factorimprovedinsulin signalingmind controlmotor controlneurotrophic factorneutralizing antibodynonhuman primatenoveloculomotororbit musclepreclinical studypreventreceptorsuccesstreatment strategyvisual deprivation
中文摘要
点击翻译按钮获取中文摘要
英文摘要
ABSTRACT
Strabismus is a common eye alignment disorder found in 3-5% of children and 3-4% of adults. If left untreated
in children, strabismus can lead to loss of stereopsis and amblyopia; the brain silences connections from the
misaligned eye, resulting in poor visual acuity. In strabismus, the ocular motor control of eye alignment is
unbalanced. One potential cause for this imbalance is disruption of the normal two-way neurotrophic factor
communication between the ocular motor system and the extraocular muscles (EOM). Our preliminary and
published data show that we can produce strabismus in infant monkeys or improve eye alignment in adult
strabismic monkeys. With those neurotrophic factors that were effective, the eye alignment was altered by 8 to
14o. We believe improved treatment efficacy for strabismus will require larger angles of correction to eye
misalignment. Gene array and our own data suggest that deficits in neurotrophic factor communication
associated with strabismus may involve multiple neurotrophic factors. Thus, to increase efficacy we predict that
we need to use a combination of neurotrophic factors. We will test two approaches. First, we predict that
combinations of neurotrophic factors that used singly on EOM had a demonstrated ability to alter eye
alignment in non-human primates. We will test efficacy of neurotrophic factor “cocktails” in adult rabbits, and
the most efficacious will be tested for the ability to produce a significant eye misalignment in infant monkeys.
Second, we predict that blocking retrograde signaling of neurotrophic factors will produce a significant eye
misalignment. We will examine efficacy of mixtures of neutralizing antibodies or inhibitory binding peptides to
block binding of endogenously produced neurotrophic factors to their receptors. This will prevent retrograde
signaling by these factors, which we predict are critical for normal eye alignment. The key for success of these
experiments is the use of a sustained delivery approach. One issue that we believe precipitates surgical failure
rates is that the change in eye alignment is larger than the ability of the ocular motor system to adapt. There is
substantial evidence that there is a significant amount of inherent plasticity possible when slow adaptation
strategies are used. Our approach uses a sustained delivery method that releases low doses of neurotrophic
factors for 3 months. Our data show that unilateral treatment is sufficient to produce altered eye alignment . In
addition, the largest change in eye alignment occurs during the final month of treatment, suggesting that ocular
motor system plasticity between brainstem nuclei requires 3 months. This timing agrees with literature showing
that visual deprivation period in infant monkeys needs to approach 3 months to produce a strabismus. We will
test our most efficacious approach for its ability to correct the eye alignment in adult strabismic monkeys. Our
long term goal is to develop effective strategies for modulating neurotrophic factor signaling, whether neuron-
or muscle-derived, based on a combination treatment strategy. This will inform future choices for moving this
strabismus treatment into human patients, with the ultimate goal of preventing loss of visual acuity.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Sex as a Factor in Normal Retinal Function and Schizophrenia
-
批准号:10447908
-
项目类别:
-
资助金额:$23.25万
-
财政年份:2022
-
负责人:LINDA K. MCLOON
-
依托单位:
Sex as a Factor in Normal Retinal Function and Schizophrenia
-
批准号:10598084
-
项目类别:
-
资助金额:$19.38万
-
财政年份:2022
-
负责人:LINDA K. MCLOON
-
依托单位:
Training Program in Translational Vision Sciences
-
批准号:10004626
-
项目类别:
-
资助金额:$4.52万
-
财政年份:2016
-
负责人:LINDA K. MCLOON
-
依托单位:
Training Program in Translational Vision Sciences
-
批准号:9328086
-
项目类别:
-
资助金额:$14.21万
-
财政年份:2016
-
负责人:LINDA K. MCLOON
-
依托单位:
Training Program in Translational Vision Sciences
-
批准号:9073028
-
项目类别:
-
资助金额:$14.06万
-
财政年份:2016
-
负责人:LINDA K. MCLOON
-
依托单位:
Training Program in Translational Vision Sciences
-
批准号:9762109
-
项目类别:
-
资助金额:$8.93万
-
财政年份:2016
-
负责人:LINDA K. MCLOON
-
依托单位:
Myogenic Potential of Extraocular Muscle Satellite Cells
-
批准号:7586961
-
项目类别:
-
资助金额:$18.88万
-
财政年份:2009
-
负责人:LINDA K. MCLOON
-
依托单位:
Myogenic Potential of Extraocular Muscle Satellite Cells
-
批准号:7777277
-
项目类别:
-
资助金额:$18.69万
-
财政年份:2009
-
负责人:LINDA K. MCLOON
-
依托单位:
Novel Immunotoxin and IGF Therapy for Strabismus
-
批准号:10228548
-
项目类别:
-
资助金额:$47.99万
-
财政年份:2004
-
负责人:LINDA K. MCLOON
-
依托单位:
Novel Immunotoxin and IGF Therapy for Strabismus
-
批准号:6986087
-
项目类别:
-
资助金额:$29.0万
-
财政年份:2004
-
负责人:LINDA K. MCLOON
-
依托单位:
Novel Immunotoxin and IGF Therapy for Strabismus
-
批准号:8511649
-
项目类别:
-
资助金额:$53.04万
-
财政年份:2004
-
负责人:LINDA K. MCLOON
-
依托单位:
Novel Immunotoxin and IGF Therapy for Strabismus
-
批准号:8004985
-
项目类别:
-
资助金额:$36.13万
-
财政年份:2004
-
负责人:LINDA K. MCLOON
-
依托单位:
Novel Immunotoxin and IGF Therapy for Strabismus
-
批准号:10414024
-
项目类别:
-
资助金额:$47.99万
-
财政年份:2004
-
负责人:LINDA K. MCLOON
-
依托单位:
Novel Immunotoxin and IGF Therapy for Strabismus
-
批准号:6737351
-
项目类别:
-
资助金额:$35.73万
-
财政年份:2004
-
负责人:LINDA K. MCLOON
-
依托单位:
Novel Immunotoxin and IGF Therapy for Strabismus
-
批准号:9915913
-
项目类别:
-
资助金额:$49.48万
-
财政年份:2004
-
负责人:LINDA K. MCLOON
-
依托单位:
Novel Immunotoxin and IGF Therapy for Strabismus
-
批准号:7747975
-
项目类别:
-
资助金额:$37.63万
-
财政年份:2004
-
负责人:LINDA K. MCLOON
-
依托单位:
Novel Immunotoxin and IGF Therapy for Strabismus
-
批准号:7885074
-
项目类别:
-
资助金额:$16.55万
-
财政年份:2004
-
负责人:LINDA K. MCLOON
-
依托单位:
Novel Immunotoxin and IGF Therapy for Strabismus
-
批准号:8338294
-
项目类别:
-
资助金额:$55.16万
-
财政年份:2004
-
负责人:LINDA K. MCLOON
-
依托单位:
Novel Immunotoxin and IGF Therapy for Strabismus
-
批准号:6838760
-
项目类别:
-
资助金额:$29.7万
-
财政年份:2004
-
负责人:LINDA K. MCLOON
-
依托单位:
Novel Immunotoxin and IGF Therapy for Strabismus
-
批准号:7196097
-
项目类别:
-
资助金额:$39.25万
-
财政年份:2004
-
负责人:LINDA K. MCLOON
-
依托单位:
海外基金